Vanta Bioscience board cleared FY26 & H2 financial results.

MD Dopesh Raja Mulakala re-appointed for 3 years (shareholder approval pending). Auditors gave a clean report.

Subsidiary assets stood at ₹3.94 Cr, with H2 & FY26 net losses of ₹0.01 Cr each.